A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

• Status: Not yet recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial in normal weight and overweight but otherwise healthy subjects randomised to subcutaneous administration of ZP8396 or placebo

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Zealand Pharma

Criteria

Inclusion Criteria:

• Body Mass Index (BMI) between 21.0 and 29.9 kg/m^2, both inclusive

• Glycosylated hemoglobin (HbA1c) below 5.7 percent

• Further inclusion criteria apply

Exclusion Criteria:

• History of metabolic diseases more frequently associated with obesity, e.g. type-2-diabetes mellitus, hypertension, dyslipidemia, heart disease or stroke

• Systolic blood pressure below 90 mmHg or above139 mmHg and/or diastolic blood pressure below 50 mmHg or above 89 mmHg

• Symptoms of arterial hypotension

• Further exclusion criteria apply